Catherine Shoults

Catherine focuses on creating cloud-based tools and automation using Artificial Intelligence and Machine Learning to support investment and operational processes across the firm.
Prior to SymBiosis, she was the Director of Drug Development at Orbis Biosciences, where she led regulatory, pre-clinical, and clinical development.
Her drug development career started at Quintiles (IQVIA) in Phase I clinical development.
She earned her PhD in Biomedical Informatics with an emphasis in Artificial Intelligence and Natural Language Processing from the University of Arkansas for Medical Sciences, an MPH with an emphasis in Epidemiology of Microbial Disease from Yale University, and a BS in Biology with a minor in Chemistry from Missouri State University.